The Latest Breaking News from Moderna

Moderna stock surged Thursday after the firm beat quarterly expectations, including turning around a surprise profit.

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

Just when it looked like technology stocks took over the S&P 500 — another sector is on the rise.

How mRNA-based drugs interact with the immune system and how they are degraded in human cells can help lead to safe, durable, and effective treatments.

In a stunning achievement, Moderna recently announced that their preliminary COVID vaccine sales for 2023 have met their target. This is fantastic news for...

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

Explore the debunked claims made by the Florida State Surgeon General regarding COVID vaccines and the integration of contaminants into DNA in this insight...

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

Boots and Superdrug have confirmed they are looking at ways to sell Covid vaccines from their high street stores